1,050 Shares in Edwards Lifesciences Corp (NYSE:EW) Purchased by Ascent Wealth Partners LLC

Ascent Wealth Partners LLC bought a new position in Edwards Lifesciences Corp (NYSE:EW) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,050 shares of the medical research company’s stock, valued at approximately $201,000.

Several other institutional investors have also bought and sold shares of EW. Executive Wealth Management LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at $25,000. FTB Advisors Inc. purchased a new position in shares of Edwards Lifesciences in the first quarter valued at about $25,000. Sontag Advisory LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $26,000. Lindbrook Capital LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $27,000. Finally, Capital Financial Planning LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. 82.00% of the stock is owned by institutional investors and hedge funds.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 1,474 shares of Edwards Lifesciences stock in a transaction on Monday, April 15th. The shares were sold at an average price of $192.00, for a total value of $283,008.00. Following the transaction, the vice president now directly owns 21,132 shares in the company, valued at $4,057,344. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $174.73, for a total transaction of $5,731,144.00. Following the transaction, the chief executive officer now owns 75,926 shares in the company, valued at $13,266,549.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 133,468 shares of company stock valued at $23,822,542. Corporate insiders own 1.63% of the company’s stock.

Edwards Lifesciences stock traded down $0.75 during trading on Monday, hitting $183.99. The company had a trading volume of 1,841,100 shares, compared to its average volume of 1,328,002. The stock has a market cap of $38.73 billion, a PE ratio of 39.42, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. The company has a 50 day simple moving average of $179.62. Edwards Lifesciences Corp has a 1-year low of $134.53 and a 1-year high of $197.86. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.23 by $0.09. The business had revenue of $993.00 million during the quarter, compared to analysts’ expectations of $989.87 million. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.22 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corp will post 5.29 earnings per share for the current year.

Several equities research analysts have recently issued reports on EW shares. Stifel Nicolaus lifted their target price on Edwards Lifesciences from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group boosted their price target on Edwards Lifesciences from $195.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Credit Suisse Group boosted their price target on Edwards Lifesciences from $189.00 to $221.00 and gave the company an “outperform” rating in a report on Monday, April 15th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $175.00 to $190.00 and gave the company a “neutral” rating in a report on Wednesday, March 27th. They noted that the move was a valuation call. Finally, BMO Capital Markets boosted their price target on Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $188.10.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: Trading Options- What is a Strangle?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.